



ADULT MEDICATION GUIDELINE						
Tibolone						
Scope (Staff):	All WNHS Staff					
Scope (Area):	Obstetrics and Gynaecology					
This document should be read in conjunction with the Disclaimer.						

Q	Ш	C		Li	nl	ks
		9	`	_		110

<u>Dose</u> <u>Administration</u> <u>Monitoring</u> <u>Pregnancy and</u> <u>Breastfeeding</u>

Restrictions

Formulary: Unrestricted

Medication Class

Hormone Replacement Therapy

Presentation

Tablet: 2.5mg

Storage

Store at room temperature, below 25°C

Dose

Schedule 8 Medication

Relief of menopause symptoms

Oral: 2.5mg daily

<u>Prevention of postmenopausal osteoporosis when there is a high risk of fractures and alternative treatment is inappropriate</u>

Oral: 2.5mg daily

Monitoring

Monitor for vaginal bleeding or spotting that persists for >6 months while taking tibolone; vaginal bleeding or spotting that starts after 6 months of tibolone or that continues after tibolone is stopped.

Pregnancy

1st Trimester: Contraindicated
2nd Trimester: Contraindicated
3rd Trimester: Contraindicated

Breastfeeding

Consider alternative

Comments

Contraindicated in women with cerebrovascular or coronary artery disease

Contraindicated in severe liver disease

Contraindicated in women with a known, past or suspected breast cancer

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Menopause & Menopausal Symptoms

Gynaecology (Non-oncological)

Pre-operative Medication Management

WNHS Pharmaceutical and Medicines Management Guidelines:

WNHS Medication Management Guideline "Return and Disposal of Medications

References

Australian Medicines Handbook. Tibolone. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Aug 03]. Available from: https://amhonline.amh.net.au/

The Royal Women's Hospital. Tibolone. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Aug 03]. Available from: https://thewomenspbmg.org.au/

MIMS Australia. Tibolone (Livial®). In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 Aug 03]. Available from: https://www.mimsonline.com.au

Keywords	Tibolone, HRT, menopause, breast cancer, hormone replacement therapy, osteoporosis, endometriosis, Livial								
Document Owner:	Chief Pharmacist								
Author/ Reviewer	KEMH Pharmacy Department								
Version Info:	4.0								
Date First Issued:	July 2015	Last Reviewed:	Nov 2017		Review Date:	03/08/2021			
Endorsed by:	Medicines and TI	herapeutics Commi		Date:	19/08/2021				
NSQHS Standards Applicable:	Std 1: Clinical Governance				Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers				Std 6: Communicating for Safety				
	Std 3: Pr	reventing and Contr ciated Infection	Std 7: Blood Management						
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration					
Printed or personally saved electronic copies of this document are considered uncontrolled.									
Access the current version from WNHS HealthPoint.									

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.